INtravesical Antimicrobial Agents v STANDard Oral Antibiotics for the Treatment of Acute UTI in Women With rUTI (INSTANT)
Primary Purpose
Urinary Tract Infections
Status
Withdrawn
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Nitrofurantoin
Gentamicin
Sponsored by
About this trial
This is an interventional treatment trial for Urinary Tract Infections focused on measuring urinary tract, infection, recurrent, women
Eligibility Criteria
Inclusion Criteria:
- Ability to understand study procedures and to comply with them for the entire length of the study.
Exclusion Criteria:
- Patients who report that they are pregnant.
- Patients with a positive urine pregnancy test
- Patients with a history of renal transplantation.
- Patients with bladder augmentation procedures using bowel.
- Patients with poorly controlled Type II diabetes, Hgb A1C >6.5%
- Patients with spinal cord injury, ASIA Impairment Scale of C or higher.
- Patients with pelvic surgery within 6 months.
- Patients with urologic procedure within 6 months.
- Patients with a history of reconstructive urologic surgery, such as reflux, congenital abnormality.
- Immunocompromised patients being treated for malignancy or a history of actively treated malignancy within 5 years.
- Patients with active systemic autoimmune disease.
- Patients on systemic immunosuppression.
- Use of antibiotic prophylaxis within 6 months
- Use of antibiotics within 10 days of active infection
- Allergy/sensitivity to gentamicin or nitrofurantoin.
- Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
- Inability or unwillingness of individual to give written informed consent.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Oral Nitrofurantoin
Intravesical Gentamicin
Arm Description
Participants will randomized to oral nitrofurantoin
Participants will be randomized to intravesical gentamicin
Outcomes
Primary Outcome Measures
Change in microbiologic effect of a chronic acute Urinary Tract Infection
Microbiological culture growth of susceptible organisms obtained on day 0, compared with voided urine culture as no growth in 24-48 hours obtained at 7-10 days
Change in symptomatic relief of a chronic acute Urinary Tract Infection
Completion of a Symptom Urinary Tract Questionnaire. Tracking the symptoms in the past 24 hours. Indicating how severe and how bothersome they were. Severe ranging from 0 (Did not have) to 3 (Severe). Bothersome ranging from 0 (Not at all) to 3 (A lot)
Secondary Outcome Measures
To establish the clinical FTE needs for providing urgent intravesical treatments
Nursing needs to provide intravesical treatments of acute Urinary Tract Infections (UTI) in women with chronic recurrent UTIs. Measured in amount of participants and FTE requirement for nursing staff.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03299387
Brief Title
INtravesical Antimicrobial Agents v STANDard Oral Antibiotics for the Treatment of Acute UTI in Women With rUTI
Acronym
INSTANT
Official Title
INtravesical Antimicrobial Agents Versus STANDard Oral Antibiotics for the Treatment of Acute Urinary Tract Infection in Women With Recurrent Urinary Tract Infection (INSTANT Study)
Study Type
Interventional
2. Study Status
Record Verification Date
June 2019
Overall Recruitment Status
Withdrawn
Why Stopped
Study never recruited
Study Start Date
June 28, 2017 (Actual)
Primary Completion Date
July 5, 2018 (Actual)
Study Completion Date
July 5, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mayo Clinic
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Women have problems with oral antibiotics, including vagina and bowel infections. Also, bacteria causing urinary infections are becoming more resistant to oral antibiotis. Placement of antibiotic directly into the bladder does not cause these problems and are at doses that are may be able to stop bacteria from being resistant to antibiotics.
Detailed Description
Each participant once enrolled returns with an active Urinary Tract Infection (UTI), confirmed by urine void. Participants will complete an UTI questionnaire, and if consistent with a simple non-febrile UTI will be randomized to one of two arms: oral nitrofurantoin treatment for 7 days, or intravesical gentamicin instillation once a day for three days. Patients will be followed for symptom relief with a repeat voided urine in 7 to 10 days, and with a repeated questionnaire for symptom relief.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Urinary Tract Infections
Keywords
urinary tract, infection, recurrent, women
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Oral Nitrofurantoin
Arm Type
Active Comparator
Arm Description
Participants will randomized to oral nitrofurantoin
Arm Title
Intravesical Gentamicin
Arm Type
Active Comparator
Arm Description
Participants will be randomized to intravesical gentamicin
Intervention Type
Drug
Intervention Name(s)
Nitrofurantoin
Other Intervention Name(s)
Macrobid, Furadantin, Macrodantin
Intervention Description
Participants will receive oral Nitrofurantoin 100 mg twice daily for 7 days
Intervention Type
Drug
Intervention Name(s)
Gentamicin
Other Intervention Name(s)
Gentak, Garamycin
Intervention Description
Participants will receive intravesical via catheter Gentamicin solution 25 mg in 50cc for 3 days
Primary Outcome Measure Information:
Title
Change in microbiologic effect of a chronic acute Urinary Tract Infection
Description
Microbiological culture growth of susceptible organisms obtained on day 0, compared with voided urine culture as no growth in 24-48 hours obtained at 7-10 days
Time Frame
baseline, 7-10 days
Title
Change in symptomatic relief of a chronic acute Urinary Tract Infection
Description
Completion of a Symptom Urinary Tract Questionnaire. Tracking the symptoms in the past 24 hours. Indicating how severe and how bothersome they were. Severe ranging from 0 (Did not have) to 3 (Severe). Bothersome ranging from 0 (Not at all) to 3 (A lot)
Time Frame
baseline, 7-10 days
Secondary Outcome Measure Information:
Title
To establish the clinical FTE needs for providing urgent intravesical treatments
Description
Nursing needs to provide intravesical treatments of acute Urinary Tract Infections (UTI) in women with chronic recurrent UTIs. Measured in amount of participants and FTE requirement for nursing staff.
Time Frame
baseline, through stufy completion, an average of one year
10. Eligibility
Sex
Female
Gender Based
Yes
Gender Eligibility Description
Premenopausal or perimenopausal healthy female patients with an active urinary tract infection and at least two symptomatic and culture-proven urinary tract infections within the past 12 months
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Ability to understand study procedures and to comply with them for the entire length of the study.
Exclusion Criteria:
Patients who report that they are pregnant.
Patients with a positive urine pregnancy test
Patients with a history of renal transplantation.
Patients with bladder augmentation procedures using bowel.
Patients with poorly controlled Type II diabetes, Hgb A1C >6.5%
Patients with spinal cord injury, ASIA Impairment Scale of C or higher.
Patients with pelvic surgery within 6 months.
Patients with urologic procedure within 6 months.
Patients with a history of reconstructive urologic surgery, such as reflux, congenital abnormality.
Immunocompromised patients being treated for malignancy or a history of actively treated malignancy within 5 years.
Patients with active systemic autoimmune disease.
Patients on systemic immunosuppression.
Use of antibiotic prophylaxis within 6 months
Use of antibiotics within 10 days of active infection
Allergy/sensitivity to gentamicin or nitrofurantoin.
Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
Inability or unwillingness of individual to give written informed consent.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Deborah Lightner, MD
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Audrey N Schuetz, MD
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Links:
URL
https://www.mayo.edu/research/clinical-trials
Description
Mayo Clinic Clinical Trials
Learn more about this trial
INtravesical Antimicrobial Agents v STANDard Oral Antibiotics for the Treatment of Acute UTI in Women With rUTI
We'll reach out to this number within 24 hrs